24-h Energy Expenditure and Anti-obesity Medication (SEM-TIR)

University of Pisa

Status: Not yet enrolling

Conditions: Obesity

Treatments: Drug: anti obesity medication

Study type: Observational

Funder types: Other

Identifiers

NCT07041983

SEM-TIR

539901_2019_Santini_PRIN2017 (Other Grant/Funding Number)

Details and patient eligibility

About

This study investigates the long-term effects of anti-obesity medications (Semaglutide and Tirzepatide) on energy metabolism (24-hour energy expenditure and substrate oxidation) and body composition via Dual-energy X-ray absorptiometry (DXA)

Full description

This study will explore the long-term effects of obesity treatments, including anti-obesity medications (AOMs) such as GLP-1 receptor agonist (Semaglutide) and GIP/GLP-1 receptor agonist (Tirzepatide), on energy metabolism (24-hour energy expenditure and substrate oxidation), body composition (fat mass and fat-free mass). The study will include AOMs may lead to a state of metabolic adaptation, one of the reasons for weight regain. To date, no studies have assessed the effects of AOMs on 24-hour energy expenditure measured by using the metabolic chamber.

Enrollment: 30 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Body mass index (BMI) >= 30 kg/m² or >= 27 kg/m² with at least one weight-related comorbidity and stable body weight (±2 kg in prior 3 months)
• informed consent, adherence to study protocol, negative pregnancy test and contraception use (if applicable), and absence of cardiovascular events or end-organ damage.

Exclusion criteria

• psychiatric conditions impairing adherence, history of medullary thyroid cancer, pregnancy/lactation
• diabetes

Trial design

30 participants in 1 patient group

antiobesity medication and energy expenditure

Description:

patients with obesity for the administration anti-obesity medication (Semaglutide or Tirzepatide) for the clinical use.

Treatment:

Drug: anti obesity medication